Allurion Technologies (ALUR) investor relations material

Executive summary

• Revenue for Q1 2026 was $2.9M, down 47% year-over-year, with a net loss of $6.1M compared to $1.5M in Q1 2025.

• FDA approved the Allurion Gastric Balloon System in February 2026, expanding U.S. market potential.

• The company faces ongoing liquidity challenges, with $5.1M in cash and substantial doubt about its ability to continue as a going concern.

• Trading of common stock was suspended on the NYSE in March 2026 due to non-compliance with listing standards; shares now trade on the OTCQB Market.

Financial highlights

• Gross profit fell 70% to $1.2M, driven by lower sales and higher inventory charges.

• Operating expenses decreased 57% to $5.0M, reflecting restructuring and cost reductions.

• Cash used in operations was $3.2M in Q1 2026, with $2.9M raised from a warrant inducement transaction.

• Accumulated deficit reached $257.1M as of March 31, 2026.

Outlook and guidance

• Management expects continued operating losses and negative cash flows, with additional capital needed to fund operations.

• Strategic focus is on regulatory approvals, commercialization, and cost management.